SCHEMBL7932672

SCHEMBL7932672

COc1ccc2oc(C(=O)Nc3cccc(CNc4cccnc4N)c3)cc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.62
MAPT P10636 5/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
TP53 P04637 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TSHR P16473 1/20 0.47
AURKA O14965 4/20 0.46
AURKB Q96GD4 4/20 0.46
RPS6KB1 P23443 2/20 0.46
MAOB P27338 3/20 0.46
POLB P06746 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
ADORA1 P30542 1/20 0.46
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7944993 0.89 HPGD (0.49) BACE1MAPTNPC1RAB9ATP53
SCHEMBL7940967 0.86 BACE1 (0.57) BACE1MAPTNPC1RAB9ATP53
SCHEMBL7940374 0.86 RAB9A (0.58) BACE1MAPTNPC1RAB9ATP53
SCHEMBL7945106 0.86 AURKA (0.47) BACE1MAPTNPC1RAB9ATP53
SCHEMBL7941663 0.86 BACE1 (0.58) BACE1MAPTNPC1RAB9ATP53
SCHEMBL7944680 0.85 BACE1 (0.59) BACE1MAPTNPC1RAB9AMEN1
SCHEMBL7940344 0.84 BACE1 (0.69) BACE1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL7932681 0.83 BACE1 (0.78) BACE1MAPTAURKAAURKBRPS6KB1
SCHEMBL7933462 0.80 BACE1 (0.71) BACE1AURKAAURKBRPS6KB1
SCHEMBL7944660 0.80 BACE1 (0.62) BACE1MAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885MAPT 38/4885NPC1 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.